SARM
GW0742
SaveA PPARδ agonist closely related to cardarine (GW501516), studied preclinically for metabolic, anti-inflammatory, and exercise-mimetic effects. Not a true SARM.
Quick verdict
Similar mechanism to cardarine with less published data. No approved human use and similar safety uncertainties.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Animal studies show anti-inflammatory and lipid-modulating effects. Some preclinical evidence suggests a potentially different safety profile from GW501516, but the data is insufficient to confirm this.
Benefits
- Preclinical anti-inflammatory effects
- Lipid profile improvements in animal models
- Potential exercise-mimetic properties
Dosage notes
No human dosing established.
Side effects
- Unknown in humans
- Potential carcinogenicity risk (PPARδ class concern)
Who should be cautious
Shares the PPARδ mechanism linked to carcinogenicity concerns with GW501516. Not approved for human use.
What this page cannot tell you
Less studied than cardarine. Claims of a better safety profile are not supported by adequate comparative data.
Leaderboard scores
- Energy30
- Weight loss25
Write a review
Sign in to write a review.